NCT07180264 Trastuzumab Deruxtecan in Advanced Breast Cancer
| NCT ID | NCT07180264 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wenjin Yin |
| Condition | Advanced Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 118 participants |
| Start Date | 2025-08-28 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 118 participants in total. It began in 2025-08-28 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 and older * Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan * ECOG 0-1 Exclusion Criteria: * During pregnancy and lactation
Contact & Investigator
Wenjin Yin, M.D.
PRINCIPAL INVESTIGATOR
Renji Hospital,School of Medicine, Shanghai Jiaotong University
Frequently Asked Questions
Who can join the NCT07180264 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07180264 currently recruiting?
Yes, NCT07180264 is actively recruiting participants. Contact the research team at yinwenjin@renji.com for enrollment information.
Where is the NCT07180264 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07180264 clinical trial?
NCT07180264 is sponsored by Wenjin Yin. The principal investigator is Wenjin Yin, M.D. at Renji Hospital,School of Medicine, Shanghai Jiaotong University. The trial plans to enroll 118 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.